Key Takeaways
- • Steve Cohen's Point72 Asset Management trimmed its Amazon position by 6% and slashed its Nvidia stake by 24% between Q4 2025 and Q1 2026, taking profits after both stocks underperformed the S&P 500 year-to-date (up ~5% versus ~10% for the index).
- • Cohen increased his Boston Scientific position by 50% from the start of 2026, signaling a strategic pivot from AI leaders toward the healthcare sector and beaten-down medical device stocks.
- • Amazon and Nvidia have lagged broader market performance in 2026 despite extraordinary long-term gains—Amazon up 560% over the past decade, Nvidia up 16,000%—suggesting Cohen is rotating away from extended valuations.
- • The shift in Cohen's portfolio allocation reflects a broader market thesis that the artificial intelligence trade is maturing, with infrastructure and support companies gaining favor over early-stage AI leaders.
Summary
Steve Cohen, the billionaire hedge fund manager helming Point72 Asset Management, has executed a notable portfolio rebalancing that signals a strategic shift away from the technology sector's dominant artificial intelligence plays. According to the fund's most recent 13F filing, Cohen reduced his exposure to Amazon by 6% and dramatically cut his Nvidia holdings by 24% between the fourth quarter of 2025 and the first quarter of 2026. Concurrently, he dramatically increased his position in Boston Scientific, a medical device manufacturer, by 50% during the same period.
The timing of these moves reflects a tactical reassessment of market leadership. Both Amazon and Nvidia have underperformed the broader market in 2026, rising approximately 5% year-to-date compared to the S&P 500's roughly 10% gain. This represents a notable deceleration after sustained multi-year rallies—Amazon has gained over 560% over the past decade while Nvidia has surged more than 16,000% over the same span. Taking profits from stocks with such extended run-ups is a conventional wealth-preservation strategy, particularly as momentum shifts.
However, Cohen's portfolio moves suggest something more strategic than simple profit-taking. The reduction in exposure to core artificial intelligence hardware and cloud infrastructure leaders, coupled with the substantial increase in Boston Scientific, points to a conviction that the AI trade's early leaders may be reaching saturation. The fund's pivot appears aligned with a broader market thesis that infrastructure companies supporting AI buildout—such as hydrogen fuel cell maker Bloom Energy—may offer superior risk-adjusted returns relative to the already-well-capitalized technology giants that have driven gains throughout the AI bull market.
For institutional investors and hedge fund managers, Cohen's rebalancing offers a case study in rotation strategies during market inflection points. While Amazon and Nvidia remain significant holdings, the reduction signals confidence that valuations in these names no longer offer compelling entry points, while the healthcare sector—notably the undervalued Boston Scientific—presents more attractive asymmetric opportunities. This move reflects the sophisticated portfolio management expected from one of the market's most closely watched allocators.
The timing of these moves reflects a tactical reassessment of market leadership. Both Amazon and Nvidia have underperformed the broader market in 2026, rising approximately 5% year-to-date compared to the S&P 500's roughly 10% gain. This represents a notable deceleration after sustained multi-year rallies—Amazon has gained over 560% over the past decade while Nvidia has surged more than 16,000% over the same span. Taking profits from stocks with such extended run-ups is a conventional wealth-preservation strategy, particularly as momentum shifts.
However, Cohen's portfolio moves suggest something more strategic than simple profit-taking. The reduction in exposure to core artificial intelligence hardware and cloud infrastructure leaders, coupled with the substantial increase in Boston Scientific, points to a conviction that the AI trade's early leaders may be reaching saturation. The fund's pivot appears aligned with a broader market thesis that infrastructure companies supporting AI buildout—such as hydrogen fuel cell maker Bloom Energy—may offer superior risk-adjusted returns relative to the already-well-capitalized technology giants that have driven gains throughout the AI bull market.
For institutional investors and hedge fund managers, Cohen's rebalancing offers a case study in rotation strategies during market inflection points. While Amazon and Nvidia remain significant holdings, the reduction signals confidence that valuations in these names no longer offer compelling entry points, while the healthcare sector—notably the undervalued Boston Scientific—presents more attractive asymmetric opportunities. This move reflects the sophisticated portfolio management expected from one of the market's most closely watched allocators.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.